bimekizumab vs Lecankitug
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-17A/F · full Psoriasis pipeline
bimekizumab · Bimzelx
Marketed by UCB
NCT03370133 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo- and active-controlled phase 3 trial involving 567 participants. Both prespecified clinical skin endpoints at week 16—PASI90 and Investigator’s Global Assessment response—were significantly better with bimekizumab than with placebo and ustekinumab (all p<0.001).
Next expected readout: March 2027 · NCT06506916 (registry estimate)
Reported efficacy
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16; Percentage of Participants With an Investigator's Global Assessment (IGA) Response (Clear or Almost Clear With at Least 2-Category Improvement Relative to Baseline) at Week 16: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 (Week 16): Bimekizumab 320 mg Q4W + Bimekizumab 320 mg Q4W/Q8W (RS) 86.2% vs Adalimumab (RS) 47.2% (met)
Result source: NCT03412747
Lecankitug
Marketed by Livzon Pharmaceutical Group Inc. and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | bimekizumab | Lecankitug |
|---|---|---|
| PASI 75 | 76.9% vs 2.4%+74.5 vs placeboNCT0337013310 other results
| —Not posted · NCT07746479 |
| PASI 90 | 85% vs 4.8%+80.2 vs placeboNCT0337013348 other results
| —Not posted · NCT07746479 |
| PASI 100 | 61.7% vs 48.9%vs SecukinumabNCT0353688410 other results
| —Not posted · NCT07746479 |
| sPGA 0/1 | 84.1% vs 4.8%+79.3 vs placeboNCT033701331 other result
| —Not posted · NCT07746479 |
| DLQI, change | —Trial running · NCT06506916 | —Not posted · NCT07746479 |
PASI 75
- bimekizumab
- 76.9% vs 2.4%+74.5 vs placeboNCT03370133
10 other results
- 75.9% vs 1.2% NCT03410992
- 74% vs 3% NCT06011733
- 75% vs 0% NCT05020249
- 76.5% vs 31.4% NCT03412747
- 71% vs 47.3% NCT03536884
- 93% vs 4.8% NCT02905006
- 83.7% vs 4.8% NCT02905006
- 81.4% vs 4.8% NCT02905006
- 85% vs 4.8% NCT02905006
- 61.5% vs 4.8% NCT02905006
- Lecankitug
- —Not posted · NCT07746479
PASI 90
- bimekizumab
- 85% vs 4.8%+80.2 vs placeboNCT03370133
48 other results
- 90.8% vs 1.2% NCT03410992
- 94% vs 3% NCT06011733
- 81.3% vs 0% NCT05020249
- 86.2% vs 47.2% NCT03412747
- 85% vs 2.4% NCT03370133
- 85.5% vs 74.3% NCT03536884
- 79.1% vs 0% NCT02905006
- 72.1% vs 0% NCT02905006
- 67.4% vs 0% NCT02905006
- 75% vs 0% NCT02905006
- 46.2% vs 0% NCT02905006
- 100% vs 83.8% NCT03010527
- 100% vs 81.1% NCT03010527
- 100% vs 67.6% NCT03010527
- 86% vs 0% NCT02905006
- 97% vs 45.9% NCT03010527
- 96.7% vs 83.8% NCT03010527
- 96.7% vs 81.1% NCT03010527
- 100% vs 67.6% NCT03010527
- 69.8% vs 0% NCT02905006
- 100% vs 45.9% NCT03010527
- 92.7% vs 83.8% NCT03010527
- 96.4% vs 81.1% NCT03010527
- 96.4% vs 67.6% NCT03010527
- 58.1% vs 0% NCT02905006
- 100% vs 45.9% NCT03010527
- 100% vs 83.8% NCT03010527
- 100% vs 81.1% NCT03010527
- 83.3% vs 67.6% NCT03010527
- 66.7% vs 45.9% NCT03010527
- 62.5% vs 83.8% NCT03010527
- 62.5% vs 81.1% NCT03010527
- 50% vs 67.6% NCT03010527
- 50% vs 45.9% NCT03010527
- 64.3% vs 83.8% NCT03010527
- 64.3% vs 81.1% NCT03010527
- 57.1% vs 67.6% NCT03010527
- 67.5% vs 0% NCT02905006
- 42.9% vs 45.9% NCT03010527
- 100% vs 83.8% NCT03010527
- 78.9% vs 83.8% NCT03010527
- 100% vs 81.1% NCT03010527
- 78.9% vs 81.1% NCT03010527
- 100% vs 67.6% NCT03010527
- 73.7% vs 67.6% NCT03010527
- 41% vs 0% NCT02905006
- 100% vs 45.9% NCT03010527
- 42.1% vs 45.9% NCT03010527
- Lecankitug
- —Not posted · NCT07746479
PASI 100
- bimekizumab
- 61.7% vs 48.9%vs SecukinumabNCT03536884
10 other results
- 58.6% vs 0% NCT03370133
- 68.2% vs 1.2% NCT03410992
- 65% vs 0% NCT06011733
- 21.9% vs 0% NCT05020249
- 60.8% vs 23.9% NCT03412747
- 55.8% vs 0% NCT02905006
- 48.8% vs 0% NCT02905006
- 27.9% vs 0% NCT02905006
- 60% vs 0% NCT02905006
- 28.2% vs 0% NCT02905006
- Lecankitug
- —Not posted · NCT07746479
sPGA 0/1
- bimekizumab
- 84.1% vs 4.8%+79.3 vs placeboNCT03370133
1 other result
- 81.9% vs 4.8% NCT03370133
- Lecankitug
- —Not posted · NCT07746479
DLQI, change
- bimekizumab
- —Trial running · NCT06506916
- Lecankitug
- —Not posted · NCT07746479
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Lecankitug: no structured comparison results are available for Psoriasis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. bimekizumab: 4 of 4 rows · Lecankitug: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | bimekizumab |
|---|---|
| Dropout rate | —320 mg Q4Wa NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3 show 46 more results—320 mg Q4W NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3 —320 mg Q4W NCT03412747 · Phase 3 · Psoriasis · phase 3 —320 mg Q4W/Q8W NCT03412747 · Phase 3 · Psoriasis · phase 3 —320 mg Q4W NCT03410992 · Phase 3 —320 mg Q4W NCT03410992 · Phase 3 —320 mg Q4W/Q4W NCT03410992 · Phase 3 —320 mg Q4W/Q4W NCT03410992 · Phase 3 —320 mg Q4W/Q8W NCT03410992 · Phase 3 —320 mg Q4W/Q8W NCT03410992 · Phase 3 —Dosage Regimen 1 NCT06011733 · Phase 3 · registry result, not featured evidence · combination —Dosage Regimen 2 NCT06011733 · Phase 3 · registry result, not featured evidence · combination —Dosage Regimen 1 NCT06011733 · Phase 3 · registry result, not featured evidence 100%320 mg Q4W NCT03598790 · Phase 3 · registry result, not featured evidence 10.4%320 mg Q4W/Q8W NCT03598790 · Phase 3 · registry result, not featured evidence 15.1%320 mg Q8W NCT03598790 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03598790 · Phase 3 · registry result, not featured evidence —320 mg Q4W/Q8W NCT03598790 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03598790 · Phase 3 · registry result, not featured evidence —320 mg Q4W NCT03536884 · Phase 3 · registry result, not featured evidence · combination —320 mg Q4W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q4W/Q4W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q4W/Q8W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q4W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q4W/Q8W NCT03536884 · Phase 3 · registry result, not featured evidence 0%320 mg Q4W NCT05020249 · Phase 3 · registry result, not featured evidence —320 mg NCT03766685 · Phase 3 · registry result, not featured evidence —320 mg NCT03766685 · Phase 3 · registry result, not featured evidence —320 mg NCT03766685 · Phase 3 · registry result, not featured evidence —320 mg NCT03766685 · Phase 3 · registry result, not featured evidence 5%320/160 mg NCT04718896 · Phase 2 · registry result, not featured evidence 0%64/32 mg NCT04718896 · Phase 2 · registry result, not featured evidence — NCT03230292 · Phase 2 · registry result, not featured evidence —320 mg Q4W NCT03010527 · Phase 2 · registry result, not featured evidence —160 mg Q4W NCT03010527 · Phase 2 · registry result, not featured evidence —64 mg Q4W NCT03010527 · Phase 2 · registry result, not featured evidence —320 mg NCT03025542 · Phase 2 · registry result, not featured evidence —320 mg + PBO NCT03025542 · Phase 2 · registry result, not featured evidence · combination —320 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence —480 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence —160 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence —160 mg w/ LD Q4W NCT02905006 · Phase 2 · registry result, not featured evidence —64 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —320 mg Q4Wa NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3 show 46 more results—320 mg Q4W NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3 —320 mg Q4W NCT03412747 · Phase 3 · Psoriasis · phase 3 —320 mg Q4W/Q8W NCT03412747 · Phase 3 · Psoriasis · phase 3 —320 mg Q4W NCT03410992 · Phase 3 —320 mg Q4W NCT03410992 · Phase 3 —320 mg Q4W/Q4W NCT03410992 · Phase 3 —320 mg Q4W/Q4W NCT03410992 · Phase 3 —320 mg Q4W/Q8W NCT03410992 · Phase 3 —320 mg Q4W/Q8W NCT03410992 · Phase 3 —Dosage Regimen 1 NCT06011733 · Phase 3 · registry result, not featured evidence · combination —Dosage Regimen 2 NCT06011733 · Phase 3 · registry result, not featured evidence · combination —Dosage Regimen 1 NCT06011733 · Phase 3 · registry result, not featured evidence 34.3%320 mg Q4W NCT03598790 · Phase 3 · registry result, not featured evidence 4%320 mg Q4W/Q8W NCT03598790 · Phase 3 · registry result, not featured evidence 6.3%320 mg Q8W NCT03598790 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03598790 · Phase 3 · registry result, not featured evidence —320 mg Q4W/Q8W NCT03598790 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03598790 · Phase 3 · registry result, not featured evidence —320 mg Q4W NCT03536884 · Phase 3 · registry result, not featured evidence · combination —320 mg Q4W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q4W/Q4W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q4W/Q8W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q4W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q4W/Q8W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q4W NCT05020249 · Phase 3 · registry result, not featured evidence —320 mg NCT03766685 · Phase 3 · registry result, not featured evidence —320 mg NCT03766685 · Phase 3 · registry result, not featured evidence —320 mg NCT03766685 · Phase 3 · registry result, not featured evidence —320 mg NCT03766685 · Phase 3 · registry result, not featured evidence —320/160 mg NCT04718896 · Phase 2 · registry result, not featured evidence —64/32 mg NCT04718896 · Phase 2 · registry result, not featured evidence — NCT03230292 · Phase 2 · registry result, not featured evidence —320 mg Q4W NCT03010527 · Phase 2 · registry result, not featured evidence —160 mg Q4W NCT03010527 · Phase 2 · registry result, not featured evidence —64 mg Q4W NCT03010527 · Phase 2 · registry result, not featured evidence —320 mg NCT03025542 · Phase 2 · registry result, not featured evidence —320 mg + PBO NCT03025542 · Phase 2 · registry result, not featured evidence · combination —320 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence —480 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence —160 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence —160 mg w/ LD Q4W NCT02905006 · Phase 2 · registry result, not featured evidence —64 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 6.1%320 mg Q4Wa NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3 show 46 more results1.6%320 mg Q4W NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3 2.5%320 mg Q4W NCT03412747 · Phase 3 · Psoriasis · phase 3 0.6%320 mg Q4W/Q8W NCT03412747 · Phase 3 · Psoriasis · phase 3 1.7%320 mg Q4W NCT03410992 · Phase 3 0%320 mg Q4W NCT03410992 · Phase 3 4.7%320 mg Q4W/Q4W NCT03410992 · Phase 3 0%320 mg Q4W/Q4W NCT03410992 · Phase 3 3%320 mg Q4W/Q8W NCT03410992 · Phase 3 0%320 mg Q4W/Q8W NCT03410992 · Phase 3 3.1%Dosage Regimen 1 NCT06011733 · Phase 3 · registry result, not featured evidence · combination 4.2%Dosage Regimen 2 NCT06011733 · Phase 3 · registry result, not featured evidence · combination 1%Dosage Regimen 1 NCT06011733 · Phase 3 · registry result, not featured evidence 7.2%320 mg Q4W NCT03598790 · Phase 3 · registry result, not featured evidence —320 mg Q4W/Q8W NCT03598790 · Phase 3 · registry result, not featured evidence 10.2%320 mg Q8W NCT03598790 · Phase 3 · registry result, not featured evidence 4.9%320 mg Q8W NCT03598790 · Phase 3 · registry result, not featured evidence 9.8%320 mg Q4W/Q8W NCT03598790 · Phase 3 · registry result, not featured evidence 9.8%320 mg Q8W NCT03598790 · Phase 3 · registry result, not featured evidence 4%320 mg Q4W NCT03536884 · Phase 3 · registry result, not featured evidence · combination 2.7%320 mg Q4W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q4W/Q4W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q4W/Q8W NCT03536884 · Phase 3 · registry result, not featured evidence 4.2%320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence 3.7%320 mg Q4W NCT03536884 · Phase 3 · registry result, not featured evidence 8.9%320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence 11.1%320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence 1.5%320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence 6.8%320 mg Q4W/Q8W NCT03536884 · Phase 3 · registry result, not featured evidence 0%320 mg Q4W NCT05020249 · Phase 3 · registry result, not featured evidence 0%320 mg NCT03766685 · Phase 3 · registry result, not featured evidence 0%320 mg NCT03766685 · Phase 3 · registry result, not featured evidence 0%320 mg NCT03766685 · Phase 3 · registry result, not featured evidence 0%320 mg NCT03766685 · Phase 3 · registry result, not featured evidence 10%320/160 mg NCT04718896 · Phase 2 · registry result, not featured evidence 14.3%64/32 mg NCT04718896 · Phase 2 · registry result, not featured evidence 7% NCT03230292 · Phase 2 · registry result, not featured evidence 7.7%320 mg Q4W NCT03010527 · Phase 2 · registry result, not featured evidence 6.3%160 mg Q4W NCT03010527 · Phase 2 · registry result, not featured evidence 6.7%64 mg Q4W NCT03010527 · Phase 2 · registry result, not featured evidence 5.9%320 mg NCT03025542 · Phase 2 · registry result, not featured evidence 6.3%320 mg + PBO NCT03025542 · Phase 2 · registry result, not featured evidence · combination 0%320 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence 2.3%480 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence 0%160 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence 0%160 mg w/ LD Q4W NCT02905006 · Phase 2 · registry result, not featured evidence 0%64 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 320 mg Q4Wa nasopharyngitis 21.8% (placebo 8.4%) oral candidiasis 15.2% (placebo 0%) upper respiratory tract infection 9.1% (placebo 2.4%) NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3 show 43 more results320 mg Q4W nasopharyngitis 9.3% (placebo 8.4%) oral candidiasis 8.7% (placebo 0%) headache 3.4% (placebo 0%) NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3 320 mg Q4W nasopharyngitis 20.3% oral candidiasis 9.5% diarrhoea 5.1% NCT03412747 · Phase 3 · Psoriasis · phase 3 320 mg Q4W/Q8W nasopharyngitis 16.8% oral candidiasis 11.8% upper respiratory tract infection 7.5% NCT03412747 · Phase 3 · Psoriasis · phase 3 320 mg Q4W nasopharyngitis 6.6% (placebo 4.7%) oral candidiasis 6% (placebo 0%) upper respiratory tract infection 4% (placebo 8.1%) NCT03410992 · Phase 3 320 mg Q4W nasopharyngitis 4.3% (placebo 4.7%) neutropenia 4.3% (placebo 0%) oral candidiasis 4.3% (placebo 0%) NCT03410992 · Phase 3 320 mg Q4W/Q4W oral candidiasis 11.3% (placebo 0%) upper respiratory tract infection 11.3% (placebo 8.1%) nasopharyngitis 10.4% (placebo 4.7%) NCT03410992 · Phase 3 320 mg Q4W/Q4W body tinea 14.3% (placebo 0%) neutropenia 14.3% (placebo 0%) psoriasis 14.3% (placebo 4.7%) NCT03410992 · Phase 3 320 mg Q4W/Q8W nasopharyngitis 23% (placebo 4.7%) oral candidiasis 9% (placebo 0%) upper respiratory tract infection 8% (placebo 8.1%) NCT03410992 · Phase 3 320 mg Q4W/Q8W dental caries 25% (placebo 1.2%) impetigo 25% (placebo 1.2%) rib fracture 25% (placebo 0%) NCT03410992 · Phase 3 Dosage Regimen 1 upper respiratory tract infection 18.5% (placebo 6.1%) injection site pain 5.4% (placebo 3%) hyperlipidaemia 3.8% (placebo 6.1%) NCT06011733 · Phase 3 · registry result, not featured evidence · combination Dosage Regimen 2 hepatic function abnormal 7.3% (placebo 0%) eczema 5.2% (placebo 0%) latent tuberculosis 5.2% (placebo 0%) NCT06011733 · Phase 3 · registry result, not featured evidence · combination Dosage Regimen 1 upper respiratory tract infection 21% (placebo 6.1%) hyperlipidaemia 5% (placebo 6.1%) injection site pain 5% (placebo 3%) NCT06011733 · Phase 3 · registry result, not featured evidence 320 mg Q4W nasopharyngitis 19.3% oral candidiasis 16.1% upper respiratory tract infection 8.2% NCT03598790 · Phase 3 · registry result, not featured evidence 320 mg Q8W corona virus infection 14.3% nasopharyngitis 12.5% oral candidiasis 10.4% NCT03598790 · Phase 3 · registry result, not featured evidence 320 mg Q8W corona virus infection 15% nasopharyngitis 6.2% oral candidiasis 5.8% NCT03598790 · Phase 3 · registry result, not featured evidence 320 mg Q4W/Q8W corona virus infection 19.5% oral candidiasis 14.6% dermatitis contact 9.8% NCT03598790 · Phase 3 · registry result, not featured evidence 320 mg Q8W corona virus infection 5.9% oral candidiasis 5.9% dermatitis contact 3.9% NCT03598790 · Phase 3 · registry result, not featured evidence 320 mg Q4W nasopharyngitis 16.6% oral candidiasis 13.4% upper respiratory tract infection 6.2% NCT03536884 · Phase 3 · registry result, not featured evidence · combination 320 mg Q4W nasopharyngitis 12.6% oral candidiasis 10.5% upper respiratory tract infection 4.3% NCT03536884 · Phase 3 · registry result, not featured evidence 320 mg Q8W oral candidiasis 16.7% nasopharyngitis 15.3% upper respiratory tract infection 9.8% NCT03536884 · Phase 3 · registry result, not featured evidence 320 mg Q4W oral candidiasis 13.3% nasopharyngitis 11.6% urinary tract infection 6.5% NCT03536884 · Phase 3 · registry result, not featured evidence 320 mg Q8W nasopharyngitis 9.9% oral candidiasis 8.5% corona virus infection 7.8% NCT03536884 · Phase 3 · registry result, not featured evidence 320 mg Q8W corona virus infection 22.2% arthropod bite 11.1% basal cell carcinoma 11.1% NCT03536884 · Phase 3 · registry result, not featured evidence 320 mg Q8W corona virus infection 10.6% oral candidiasis 6.1% nasopharyngitis 4.5% NCT03536884 · Phase 3 · registry result, not featured evidence 320 mg Q4W/Q8W corona virus infection 16.9% oral candidiasis 8.5% basal cell carcinoma 3.4% NCT03536884 · Phase 3 · registry result, not featured evidence 320 mg Q4W corona virus infection 21.9% (placebo 6.7%) eczema 6.3% (placebo 0%) tinea pedis 6.3% (placebo 0%) NCT05020249 · Phase 3 · registry result, not featured evidence 320 mg injection site pain 0% injection site reaction 0% NCT03766685 · Phase 3 · registry result, not featured evidence 320 mg injection site pain 5.3% injection site reaction 0% NCT03766685 · Phase 3 · registry result, not featured evidence 320 mg injection site pain 0% injection site reaction 0% NCT03766685 · Phase 3 · registry result, not featured evidence 320 mg injection site reaction 5.3% injection site pain 0% NCT03766685 · Phase 3 · registry result, not featured evidence 320/160 mg nasopharyngitis 45% urinary tract infection 25% alanine aminotransferase increased 10% NCT04718896 · Phase 2 · registry result, not featured evidence 64/32 mg nasopharyngitis 33.3% upper respiratory tract infection 23.8% pharyngitis 14.3% NCT04718896 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 18.6% nasopharyngitis 16.3% gamma-glutamyltransferase increased 11.6% NCT03230292 · Phase 2 · registry result, not featured evidence 320 mg Q4W oral candidiasis 16.5% nasopharyngitis 12.1% upper respiratory tract infection 9.9% NCT03010527 · Phase 2 · registry result, not featured evidence 160 mg Q4W nasopharyngitis 13.5% oral candidiasis 11.7% upper respiratory tract infection 9% NCT03010527 · Phase 2 · registry result, not featured evidence 64 mg Q4W hypertension 13.3% nasopharyngitis 13.3% psoriasis 13.3% NCT03010527 · Phase 2 · registry result, not featured evidence 320 mg nasopharyngitis 23.5% alanine aminotransferase increased 17.6% gamma-glutamyltransferase increased 17.6% NCT03025542 · Phase 2 · registry result, not featured evidence 320 mg + PBO upper respiratory tract infection 18.8% hyperkalaemia 12.5% urinary tract infection 12.5% NCT03025542 · Phase 2 · registry result, not featured evidence · combination 320 mg Q4W nasopharyngitis 14% (placebo 4.8%) oral candidiasis 7% (placebo 0%) neutropenia 4.7% (placebo 0%) NCT02905006 · Phase 2 · registry result, not featured evidence 480 mg Q4W nasopharyngitis 9.3% (placebo 4.8%) arthralgia 7% (placebo 0%) headache 2.3% (placebo 0%) NCT02905006 · Phase 2 · registry result, not featured evidence 160 mg Q4W gamma-glutamyltransferase increased 7% (placebo 2.4%) nasopharyngitis 7% (placebo 4.8%) tonsillitis 4.7% (placebo 0%) NCT02905006 · Phase 2 · registry result, not featured evidence 160 mg w/ LD Q4W nasopharyngitis 7.5% (placebo 4.8%) upper respiratory tract infection 7.5% (placebo 2.4%) gamma-glutamyltransferase increased 5% (placebo 2.4%) NCT02905006 · Phase 2 · registry result, not featured evidence 64 mg Q4W nasopharyngitis 12.8% (placebo 4.8%) upper respiratory tract infection 12.8% (placebo 2.4%) arthralgia 5.1% (placebo 0%) NCT02905006 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 43 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
bimekizumab
show 116 more results
show 2 more results
show 15 more results
show 2 more results
show 10 more results
show 3 more results
show 3 more results
show 3 more results
show 2 more results
show 7 more results
show 21 more results
show 6 more results
+ 45 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: bimekizumab's landscape · Lecankitug's landscape